依达拉奉对急性ST段抬高型心肌梗死患者心功能及MCP-1的影响  

Effects of Edaravone on left ventricular function and MCP-1 in patients with acute ST segment elevation myocardial infarction

作　　者：高启军[1] 尹琼[1] 万书平[1] 魏辉[1] 刘曼华[1] 

机构地区：[1]天门市第一人民医院心内科,湖北省天门市431700

出　　处：《中国心血管病研究》2015年第6期533-535,共3页Chinese Journal of Cardiovascular Research

摘　　要：目的 研究依达拉奉对急性心肌梗死患者再灌注损伤的影响.方法 96例拟行溶栓治疗的急性ST段抬高型心肌梗死患者在溶栓之前随机分为依达拉奉组和对照组.依达拉奉组患者入院后立即给予30 mg依达拉奉静脉滴注（n=48）,对照组患者给予生理盐水静滴（n=48）.监测两组TNI、CK-MB、MCP-1,并于入院后及2周时查心脏超声心动图,测左心功能.结果 与对照组比绞,依达拉奉组CK-MB峰值明显下降[（193±49）U/L比（221±58）U/L,P=0.01],TNI峰值明显下降[（16.3±4.7）ng/ml比（18.6±5.2）ng/ml,P=0.03].第3天依达拉奉组MCP-1较对照组明显减少[（784±105）pg/ml比（857±122）pg/ml,P=0.002].入院24 h心功能明显改善[（54.6±4.9）比（51.8±5.6）,P=0.01].结论 依达拉奉可减少急性心肌梗死溶栓再灌注损伤,改善患者心功能,降低MCP-1.Objective To study the effects of Edaravone on reperfusion injury in patients with acute ST segment elevation myocardial infarction. Methods Ninety six initial acute STEMI patients were randomly assigned to receive 30 mg Edaravone（n=48） or a placebo（n=48） intravenously before reperfusion. The infarct size, serum biomarkers, MCP-1. Plasma samples were obtained before and at 24 h, 3 days after reperfusion. Results The Edaravone group had statistically lower maximum creatine kinase-MB levels [ （ 193 ±49 ）U/L vs （ 221 ±58 ）U/L, P= 0.01 ], maximum TNI levels[ （16.3±4.7）ng/ml vs （18.6±5.2）ng/m1, P=-0.03 ] and plasma MCP-1 levels on day 3 after reperfusion [（784±105）pg/ml vs （857±122）pg/ml, P=0.002]. LVEF was statistically higher in the Edar- avone group than in the control group[ （54.6±4.9） vs （51.8±5.6）, P=-0.01 ] reperfusion arrhythmia were not signifi- cantly between the two groups （11,18 respective P=0.1 ）. Conclusion The present study suggests that the Edar- avone administration just prior to reperfusion might reduce oxidative stress and improve the clinical outcomes of AMI patients.

关 键 词：依达拉奉 氧自由基 心肌梗死 

分 类 号：R542.22[医药卫生—心血管疾病]